anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present disclosure provides compositions and methods for increasing bone growth and/or enhancing wound healing, for example, fracture repair. The disclosure provides recombinant nucleic acids useful for promoting bone growth. For example, the disclosure provides recombinant nucleic acids that encode a fibroblast growth factor-2 (FGF-2) analog. The disclosure also provides vectors and cells incorporating these nucleic acids, as well as FGF-2 analogs encode by them. The disclosure also provides a mouse system of bone marrow transplantation and methods for producing as well as methods for using the system. Methods for inducing division and/or inducing differentiation of a hematopoietic stem cell are also provided, as are methods for enhancing bone growth and/or wound repair (for example, fracture repair).
BACKGROUND: Two prefusion F protein-based vaccines, Arexvy and Abrysvo, have been approved by Health Canada for protecting older adults against respiratory syncytial virus (RSV)-associated lower respiratory tract disease. We estimated the health benefits and cost-effectiveness of these vaccines under a publicly funded single-dose vaccination program in Ontario that targets residents of long-term care homes (LTCHs). Additionally, we evaluated an extended program that broadens vaccination to include community-dwelling older adults.
METHODS: A discrete-event simulation model was parameterised with the burden of RSV disease including outpatient care, hospitalisation, and death among adults aged 60 years or older in Ontario, Canada. Accounting for direct and indirect costs (in 2023 Canadian dollars) associated with RSV-related outcomes, we calculated the net monetary benefit using quality-adjusted life-year (QALY) gained, and determined the range of price-per-dose (PPD) for vaccination programs to be cost-effective from both healthcare and societal perspectives over two RSV seasons. The incremental cost-effectiveness ratio (ICER) was calculated to estimate the additional costs required to gain one QALY.
RESULTS: Using a willingness-to-pay of $50,000 per QALY gained, we found that vaccinating 90% of residents in LTCHs with Arexvy would be cost-effective from a societal perspective for a PPD up to $163, producing a mean ICER value of $49,984 (95% CI: $47,539 to $52,704) per QALY gained with a two-year budget impact of $463,468 per 100,000 older adults. The reduction of hospitalizations was estimated at 7.0% compared to the no-vaccination scenario. Extending the program to include community-dwelling older adults with a 74% coverage akin to influenza vaccination, Arexvy remains cost-effective for a PPD up to $139, with a mean ICER value of $49,698 (95% CI: 48,022 to 51,388) per QALY gained and a two-year budget impact of $8.63 million. Compared to the no-vaccination scenario, the extended program resulted in a 57.3% reduction in RSV-related hospitalisations.
CONCLUSIONS: Vaccinating residents of LTCHs against RSV disease would be cost-effective depending on PPD; extending the program to community-dwelling older adults would provide substantial health benefits, averting significant direct healthcare costs and productivity losses.
Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by a concerning rise in prevalence. It is projected that the number of affected individuals will reach a staggering 150 million by 2050. While recent advancements in monoclonal antibodies targeting Aβ have shown some clinical effects, there is an urgent need for improved therapies to effectively address the impeding surge of AD patients worldwide. To achieve this, a deeper understanding of the intricate mechanisms underlying the disease is crucial. In recent years, mounting evidence has underscored the vital role of the innate immune system in AD pathology. However, limited findings persist regarding the involvement of the adaptive immune system. Here, we report on the impact of the adaptive immune system on various aspects of AD by using AppNL-G-F mice crossed into a Rag2-/- background lacking mature adaptive immune cells. In addition, to simulate the continuous exposure to various challenges such as infections that is commonly observed in humans, the innate immune system was activated through the repetitive induction of peripheral inflammation. We observed a remarkably improved performance on complex cognitive tasks when a mature adaptive immune system is absent. Notably, this observation is pathologically associated with lower Aβ plaque accumulation, reduced glial activation, and better-preserved neuronal networks in the mice lacking a mature adaptive immune system. Collectively, these findings highlight the detrimental role of the adaptive immune system in AD and underscore the need for effective strategies to modulate it for therapeutic purposes.
Coronary artery bypass graft surgery (CABG) is an extremely invasive medical intervention.It is postulated that even under these conditions, treatment outcome is substantially determined by non-specific effects, e.g. patient's expectation. Targeting patients' expectations at an early stage might have potential to optimize outcomes after cardiac surgery. The purpose of this research project is to optimize patients' outcome expectations before undergoing cardiac surgery through a brief psycho-educational program. Using a randomized controlled design, 180 patients who are scheduled to undergo elective CABG are randomly assigned either to standard medical information alone, or to an additional expectation manipulation intervention (EMI) during the two weeks before surgery, or to an attention-control group ("supportive therapy"). The main goal is to enhance positive expectations (surgery 'non-specific effects') about favorable outcome through EMI, about coping abilities to deal with adverse events, and to reduce negative expectations and misconceptions. Assessment takes place before and after EMI, 10 days after surgery and 6 months later; same assessment points are used for the 2 control conditions. Primary outcome is disability, which has been shown to be strongly determined by patient's expectation in previous studies. Moreover, psychological and biological predictors and mediators of treatment success are analyzed. A positive result for this expectation intervention would have major implications for clinical practice. In order to optimize treatment outcome, it is not only necessary to improve the treatment-specific procedures (e.g., cardiac surgery) but also to address non-specific factors such as patients' expectations.
In Type 1 Together, families will work with other families who have experience using CGM (Peer Mentors) to overcome common barriers to CGM use. Families in the Type 1 Together program will also have access to CGM-specific educational materials, a digital journal to facilitate patient-provider communication around issues with CGM, and social determinant of health screening and intervention with a diabetes community health worker.
The medical device, and in particular the mobile medical device, preferably comprises a communication unit enabling an operator of the medical device to exchange information with a remote medical specialist. A medical device is disclosed that facilitates improved support of its operator by a remote medical professional. Further, the medical device queries information about the experience level of the operator to assess the required level of support. Furthermore, the medical device queries for information about the use and urgency. Depending on this information, the medical device determines a data set that may need to be sent to a remote medical professional. In addition, the medical device determines a required transmission rate so that the remote medical professional can effectively support the operator of the medical device. Last but not least, the communication unit of the medical device requests and establishes one or more communication connections with appropriate communication priority to achieve the required transmission rate.
Patients receive treatment by their treating physician as described in the INSIGNA protocol based on their designated treatment arm. Patients then undergo stool sample collection, complete questionnaires and functional status assessments, such as short physical performance battery over 10 minutes and 6 minute walk test, at baseline, days 40 (cycle 3), day 80 (cycle 5), day 180 (cycle 10) and end of treatment (up to 2 years).
The invention belongs to the technical field of daily chemical products and relates to liquid cleaning agent, in particular to bath fluid containing a silk fibroin peptide-based surfactant. Based mass percentage, the bath fluid comprises the following components: a silk fibroin peptide-based surfactant, an alkyl polyglycoside surfactant, dodecyl betaine, a humectant, an electrolyte and the like. The silk fibroin peptide-based surfactant takes an aliphatic chain as a hydrophobic group and a silk peptide chain as a hydrophilic group, wherein the hydrophobic group and the hydrophilic group are connected by an amido bond. The preparation method of the bath fluid comprises: hydrolyzing silk fibroin prepared from natural baves to obtain a silk peptide with a molecular weight ranging from 300 to 3,000; and reacting the silk peptide with fatty acyl chloride. The bath fluid provided by the invention can effectively increase nutrients of skin and activity and elasticity of skin cells, and promote metabolism of cells. The obtained product is safe, environment-friendly and highly biodegradable and meets requirements of green chemistry.
The study will be conducted in two (2) parts and each part will consist of a ramp-up period, dose escalation and dose expansion portions. The duration of the ramp-up period will depend on the dose schedule being tested and will be conducted for both monotherapy and combination therapy. The ramp-up will consist of treatment with APG-2575 given once a day starting at 20 mg on Day 1, 50 mg on Day 2, 100 mg on Day 3, 200 mg on Day 4, 400 mg on Day 5¸ 600 mg on Day 6, 800 mg on Day 7, 1000 mg on Day 8 and 1200 mg on Day 9. Scheduled maximum cohort doses for evaluation will start at 200 mg of APG-2575 to a maximum of 1200 mg of APG-2575. Consequently, patients with a scheduled maximum dose of 200 mg will have a 3-day ramp-up period, those scheduled at 400 mg, a 4-day ramp-up, and those scheduled at 600 mg, a 5-day ramp-up, etc, see Figure 1. Part 1 will study APG-2575 at different dose levels as monotherapy using a 3+3 dose escalation design with dose expansion at RP2D. Part 2 will be combination of APG-2575 with rituximab or acalabrutinib or voruciclib Part 2 will be a 3+3 dose escalation of combination APG-2575 plus rituximab or acalabrutinib or voruciclib. Expansion cohorts at RP2D for the respective combinations will be conducted to further evaluate safety and anticancer activity
Once participants consent, they will complete the three demographic questions and their familiarity with virtual reality. Participants will also complete the Patient Health Questionnaire-8(PHQ-8), Affinity for Technology Interaction scale (ATI), Positive and Negative Affect Schedule (PANAS), and the mood sliding scale. Participants will then be informed that they are going to watch a short clip and press play to watch a 2-minute video of Lion King. After the sad mood induction, participants will complete the PANAS and a mood slider scale. Participants will then be randomly assigned to the virtual reality or control condition. In the virtual reality condition, participants will be asked to complete the first course a virtual reality game called "The Climb". In the control condition, participants will be told that they will be watching a video of a virtual environment climbing game and then be asked to copy all hand movements as accurately as they can. After completing either the virtual reality or control condition, individuals will then complete the PANAS, mood scale, temple presence inventory, three feedback questions, net promoter question, and an open-ended question on improving the activity they just completed. Participants will then be debriefed about the study and compensated for their time.
PROBLEM TO BE SOLVED: To obtain a pack cosmetic for face and body, having excellent lightness of spreading and stability without dripping by including a thickening agent and a clay mineral. SOLUTION: This pack cosmetic is obtained by including pref. 0.7-1.4 wt.%, based on the total weight of the cosmetic, of a thickening.agent (e.g. hydroxyethyl cellulose, xanthan gum, carrageenan) and pref. 37-45 wt.% of a clay mineral (pref. silicate mineral, talc, mica) and has a viscosity of 20,000-80,000 Pa.s (30 deg.C) in the system. More precisely, this pack cosmetic is obtained e.g. by mixing the thickening agent and the clay mineral with other ingredients such as water, a film-forming agent, a humectant, a surfactant and a polyhydric alcohol, followed by dispersion, dissolving the resultant dispersed mixture under heating, adding an alcohol phase such as ethanol thereto, then, mixing and dissolving. This pack cosmetic includes e.g. a type to be dried and removed, a peel-off type and a type to be wiped off or to be washed away.
The invention relates to clinical application of traditional Chinese medicines and mainly relates to the field of application of a traditional Chinese medicine composition in preventing and treating non-alcoholic fatty liver disease. The traditional Chinese medicine composition for preventing and treating non-alcoholic fatty liver disease is characterized by being prepared from the following active pharmaceutical ingredients in parts by weight: 5-25 parts of semen cassiae, 5-20 parts of lotus leaf, 5-20 parts of orange peel and 10-50 parts of oyster and more specifically 10-20 parts of semen cassiae, 10-15 parts of lotus leaf, 10-12 parts of orange peel and 20-40 parts of oyster. Furthermore, the composition and pharmaceutically acceptable accessories can be made into tablets, capsules, granules, mixture, oral liquid and injection. In the formula, the semen cassiae is the monarch and realizes the functions of clearing liver and dissipating heat; the lotus leaf serves as a minister for aroma and dampness elimination; and the and the raw oyster are together used as assistants, the orange peel has the functions of invigorating spleen, drying dampness and resolving phlegm, and the raw oyster has the functions of pacifying liver and dissipating mass. The medicines together realize the functions of clearing heat and eliminating dampness and resolving phlegm and dissipating mass. In-vivo experiments prove that the traditional Chinese medicine composition provided by the invention has an obvious effect in resisting non-alcoholic fatty liver disease.
BACKGROUND: Surgical site infections (SSI) are a significant concern following traumatic brain injury (TBI) surgery and often stem from the skin's microbiota near the surgical site, allowing bacteria to penetrate deeper layers and potentially causing severe infections in the cranial cavity. This study investigated the relationship between scalp skin microbiota composition and the risk of SSI after TBI surgery in sub-Saharan Africa (SSA).
METHODS: This was a prospective cohort study, enrolling patients scheduled for TBI surgery. Sterile skin swabs were taken from the surrounding normal skin of the head and stored for analysis at -80°Celcius. Patients were monitored postoperatively for up to three months to detect any occurrences of SSI. 16S rRNA sequencing was used to analyze the skin microbiota composition, identifying different taxonomic microorganisms at the genus level. The analysis compared two groups: those who developed SSI and those who did not.
RESULTS: A total of 57 patients were included, mostly male (89.5%) with a mean age of 26.5 years, predominantly from urban areas in Uganda and victims of assault. Graphical visualization and metagenomic metrics analysis revealed differences in composition, richness, and evenness of skin microbiota within samples (α) or within the community (β), and showed specific taxa (phylum and genera) associated with either the group of SSI or the No SSI.
CONCLUSIONS: Metagenomic sequencing analysis uncovered several baseline findings and trends regarding the skin microbiome's relationship with SSI risk. There is an association between scalp microbiota composition (abundancy and diversity) and SSI occurrence following TBI surgery in SSA. We hypothesize under reserve that the scalp microbiota dysbiosis could potentially be an independent predictor of the occurrence of SSI; we advocate for further studies with larger cohorts.
Monosialoganglioside GM1 (GM1) has long been used as a therapeutic agent for neurological diseases in the clinical treatment of ischemic stroke. However, the mechanism underlying the neuroprotective function of GM1 is still obscure until now. In this study, we investigated the effects of GM1 in ischemia and reperfusion (I/R) brain injury models. Middle cerebral artery occlusion and reperfusion (MCAO/R) rats were treated with GM1 (60 mg·kg-1·d-1, tail vein injection) for 2 weeks. The results showed that GM1 substantially attenuated the MCAO/R-induced neurological dysfunction and inhibited the inflammatory responses and cell apoptosis in ischemic parietal cortex. We further revealed that GM1 inhibited the activation of NFκB/MAPK signaling pathway induced by MCAO/R injury. To explore its underlying mechanism of the neuroprotective effect, transcriptome sequencing was introduced to screen the differentially expressed genes (DEGs). By function enrichment and PPI network analyses, Sptbn1 was identified as a node gene in the network regulated by GM1 treatment. In the MCAO/R model of rats and oxygen-glucose deprivation and reperfusion (OGD/R) model of primary culture of rat cortical neurons, we first found that SPTBN1 was involved in the attenuation of I/R induced neuronal injury after GM1 administration. In SPTBN1-knockdown SH-SY5Y cells, the treatment with GM1 (20 μM) significantly increased SPTBN1 level. Moreover, OGD/R decreased SPTBN1 level in SPTBN1-overexpressed SH-SY5Y cells. These results indicated that GM1 might achieve its potent neuroprotective effects by regulating inflammatory response, cell apoptosis, and cytomembrane and cytoskeleton signals through SPTBN1. Therefore, SPTBN1 may be a potential target for the treatment of ischemic stroke.
The present invention provides for peptide conjugate compositions, methods of using the peptide conjugate compositions, and pharmaceutical compositions comprising the peptide conjugate compositions. The peptide conjugate compositions comprise peptides with amino acid sequences similar to the gp120 principal neutralizing domain (PND) of HIV, gp41, and Nef (p27) of HIV and carriers which enhance immunogenicity. The peptide conjugate compositions of the present invention may comprise a multivalent cocktail of several different peptide conjugates. Also provided by present invention is a method for reducing the level of HIV titers in a mammal by administering to the mammal a peptide composition of the present invention in an amount effective to reduce the level of HIV titers. The peptide conjugate compositions of the present invention induce prolonged antibody response in serum, a high level of antibody in the mucosa, and the production of cytotoxic lymphocytes. The peptide conjugate compositions of the present invention also elicit neutralizing antibodies and decrease viral loads in a subject.
The present invention relates to a preparation for regulating blood sugar and treating diabetes and a preparation method, particularly to a preparation for treating diabetes and a preparation method. The preparation is prepared from ginseng, Chinese goldthread, mongolian snakegourd root, eucommia bark, milkvetch root, red sange root, barbary wolfberry fruit, flastem milkvetch seed, white peony root, common anemarrhena rhizome, glyburid, etc. The preparation method comprises the following processes: firstly processing the 9 traditional Chinese medicines of the mongolian snakegourd root, etc. through decoction, extraction, concentration, ethanol precipitation and filtration to obtain supernatant fluid; distilling the supernatant fluid for removing the ethanol, concentrating and drying the distilled supernatant fluid to obtain dry extract, and then crushing the dry extract to obtain dry extract powder; crushing the ginseng and the Chinese goldthread, sieving the powder, mixing the powder with the dry extract powder and the glyburide, and then adding a molding auxiliary agent to obtain the product of the preparation. Owing to the effective combination and the synergic action of the traditional Chinese medicines and western medicines, the preparation can be used for obviously lowering the blood sugar, the urine sugar and the glycosylated hemoglobin of patients with diabetes, decreasing the lipid metabolic disorder of the patients with diabetes and removing the symptoms the deficiency of both qi and blood, and has the advantages of safe medicinal application and no obvious toxic effect and side effect. The preparation is a safe effective medicine for treating the symptoms the deficiency of both the qi and the blood of type II diabetes. The preparation method of the present invention has the advantages of feasibility, simplicity and stability.
A dry needling treatment was performed on trapezius trigger point number 2, and just after thar, a TENS curretn was applied. Patients will be reassed on fourth day after treatment.
BACKGROUND: Eosinophilic esophagitis is a chronic inflammatory disorder of the esophagus. This real-world study used patient and physician surveys to describe the clinical characteristics and disease burden of eosinophilic esophagitis-overall and in a subgroup of patients with dysphagia despite treatment.
METHODS: Data analyzed in this study were collected in 2020 from US and EU patients with eosinophilic esophagitis. Eligible patients were aged ≥ 12 years with a diagnosis of eosinophilic esophagitis, had an esophageal count of ≥ 15 eosinophils/high-power field at diagnosis, and were currently prescribed treatment for eosinophilic esophagitis.
RESULTS: Overall, 1001 patients were included, of whom 356 (36%) had dysphagia despite treatment. Demographics and clinical characteristics were similar in both populations. The severity of eosinophilic esophagitis was mild in more patients overall (69%) versus those with dysphagia despite treatment (48%). Patient disease history was similar in both populations, with some exceptions: common patient-reported symptoms were dysphagia (70% and 86%) and heartburn/acid reflux (55% and 49%), and common physician-reported symptoms were dysphagia (75% and 91%) and food impaction (46% and 52%). Treatment history was similar in both populations; overall, the most common treatments were proton pump inhibitors (83%) and topical corticosteroids (51%). Patients reported slightly more days with symptoms, higher impacts on activities of daily living, and slightly higher anxiety or depression in the dysphagia-despite-treatment population versus the overall population.
CONCLUSIONS: Eosinophilic esophagitis presents severe symptoms and comorbidities that substantially impact patients' well-being and quality of life. Greater awareness of and novel treatments for eosinophilic esophagitis are needed.